Top Markets
#1 Celer Network Celer Network +41.22%
#2 Gravity Gravity +22.02%
#3 Galxe Galxe +19.80%
#4 MemeCore MemeCore +12.58%
#5 Ontology Gas Ontology Gas +9.96%
#6 Cartesi Cartesi +8.25%
#7 Zilliqa Zilliqa +7.90%
#8 Synapse Synapse +7.43%
#9 Cortex Cortex +7.33%
#10 UnifAI Network UnifAI Network +7.06%
Coin of the day
Celer Network Celer Network
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Share Price
$0.1559364
Last synced: 2026-09-18
Market Cap
$195.17K
Change (1 day)
6.60%
Change (1 year)
-30.91%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
Number of shares outstanding for Fusion Antibodies plc (FAB)
Number of shares outstanding as of September 2025: 113.21M
According to Fusion Antibodies plc latest financial reports and stock price the company's current number of shares outstanding is 113.21M. At the end of March 2024 the company had 55.56M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Fusion Antibodies plc (FAB) from 2013 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 113.21M 18.07%
2025 95.88M 72.58%
2024 55.56M 113.55%
2023 26.01M 0.27%
2022 25.95M 1.91%
2021 25.46M 15.24%
2020 22.09M 0.00%
2019 22.09M 37.07%
2018 16.12M -27.04%
2017 22.09M 0.00%
2016 22.09M 0.00%
2015 22.09M 0.00%
2014 22.09M 0.00%
2013 22.09M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 124.27%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -45.07%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 249.79%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 323.03%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH